Abbott, a global healthcare leader, has reported its financial results for the fourth quarter and full-year 2024, along with its financial outlook for 2025. The company's fourth-quarter sales reached $11.0 billion, showing an increase of 7.2 percent on a reported basis and 8.8 percent on an organic basis. Full-year 2024 sales were $42.0 billion, marking a 4.6 percent increase on a reported basis and 7.1 percent on an organic basis.
In terms of specific business segments, Abbott's nutrition sales increased by 4.5 percent in the fourth quarter and 3.2 percent for the full year. Diagnostics sales grew by 1.3 percent in the fourth quarter and 1.5 percent for the full year. Established pharmaceuticals sales increased by 3.8 percent in the fourth quarter and 3.3 percent for the full year. Medical devices sales showed a strong performance, increasing by 13.7 percent in the fourth quarter and 12.4 percent for the full year.
Furthermore, Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%. The company also anticipates an adjusted operating margin between 23.5% to 24.0% of sales in 2025. Additionally, Abbott projects its full-year 2025 adjusted diluted earnings per share to be between $5.05 to $5.25.
Abbott's quarterly dividend of $0.59 per share was declared, continuing its 53-year streak of increasing dividend payouts. The company's cash dividend is payable on February 14, 2025.
The market has reacted to these announcements by moving the company's shares 0.8% to a price of $117.78. Check out the company's full 8-K submission here.
